Kiora Pharmaceuticals Inc. KPRX

$2.21 -0.08 (-3.49%)

Valuation

Market cap
10,132,000
Revenue TTM
$0
Net income TTM
$-10,840,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
24,900
Avg volume
14,498
Day's range
$2.21 – $2.28
Shares out
4,424,000
Stochastic %K
0%
Beta
-0.22
Analysts
Strong Sell
Price target
$12.00

Price

Company profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non...

Show more

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 224 9600
Website
https://www.kiorapharma.com
Address
332 Encinitas Boulevard, Suite 102, Encinitas, United States

Latest news

Stocktwits

focafoca99 Sep 8, 11:46 AM
$KPRX introduced its new EVP of Clinical Development, Keith Lane, with a $350K salary and $75K sign-on bonus.
0 replies
focafoca99 Aug 19, 11:15 AM
$KPRX signed an exclusive license deal with CKD for its KIO-301 eye drug, including a $1 M up-front payment.
0 replies
StocktwitsNews Aug 7, 5:59 PM
KPRX Q2 2026 Earnings Summary $KPRX https://stocktwits.com/news/earnings/earnings/kprx-q2-2026-earnings-summary/cZoffkmRJ9V
0 replies
StocktwitsEarnings Aug 7, 12:15 PM
$KPRX Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.34 up 37.04% YoY
0 replies
newsfile_corp Aug 7, 11:02 AM
https://nfne.ws/308423 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #CorporateUpdate #Earnings #QuarterlyResul
0 replies
Verudoxi Jul 9, 4:19 PM
$KPRX Good stock. I'm in.
0 replies
Doozio Jul 3, 4:50 PM
$KPRX out of the tightness let’s bang bro ENTA 🐒🍌🧠⏰♾️
0 replies
newsfile_corp Jul 2, 11:01 AM
https://nfne.ws/303675 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing
0 replies